Journal of Clinical Chemistry and Laboratory Medicine
Open Access

Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, 44106, Cleveland, Ohio, USA

Publications

• Research Article   
  HRI Inhibition by Hemin as a Novel Targeted Therapy for Glioblastoma via the Integrated Stress Response
  Author(s): Xingchuan Ma*
  
  The treatment of Glioblastoma Multiforme (GBM), a highly malignant brain tumor, is critically hindered by the ineffectiveness of current modalities such as surgery, radiation and chemotherapy. These traditional methods fail to completely remove the tumor mass and lack the ability to discriminate between cancerous and normal brain cells, often resulting in collateral damage to healthy tissue and recurrence of the disease. This underscores an urgent necessity to develop novel therapeutic strategies that can target tumor cells with precision, offering hope for improved survival rates and quality of life for GBM patients. This study investigates targeted therapy, focusing on the Integrated Stress Response (ISR) that cancer cells harness to survive hypoxic stress. Specifically, it demonstrates that Eukaryotic Translation Initiation Factor 2 Alpha Kinase 1 (EIF2AK1), which encodes .. View More»
  DOI: 10.35248/2736- 6588.24.7.286

  Abstract HTML PDF